The company does not have long-term supply agreements for all components of its pharmaceutical product candidates, which presents risks in obtaining required components in sufficient quantities, quality, timing, or cost. Product revenues primarily derive from key excipients included in POSIMIR, Methydur Sustained Release Capsules, and other products. In 2024, Indivior accounted for 78% of the company's total revenue. Manufacturing pharmaceutical product candidates involves complex processes requiring qualified facilities. The company has established development and commercial manufacturing agreements with third parties for larsucosterol and POSIMIR. The manufacturing agreement for POSIMIR is currently assigned to Innocoll until May 6, 2025. The company operates a small multi-discipline manufacturing facility in California that produces research and clinical supplies, including larsucosterol dosage forms, and manufactures certain key components for POSIMIR and Methydur. Future manufacturing capacity may be expanded through third-party manufacturers to meet demand.
Durect's Comment on Supply Chain
The company does not have long-term supply agreements for all components of its pharmaceutical product candidates, which presents risks in obtaining required components in sufficient quantities, quality, timing, or cost. Product revenues primarily derive from key excipients included in POSIMIR, Methydur Sustained Release Capsules, and other products. In 2024, Indivior accounted for 78% of the company's total revenue. Manufacturing pharmaceutical product candidates involves complex processes requiring qualified facilities. The company has established development and commercial manufacturing agreements with third parties for larsucosterol and POSIMIR. The manufacturing agreement for POSIMIR is currently assigned to Innocoll until May 6, 2025. The company operates a small multi-discipline manufacturing facility in California that produces research and clinical supplies, including larsucosterol dosage forms, and manufactures certain key components for POSIMIR and Methydur. Future manufacturing capacity may be expanded through third-party manufacturers to meet demand.
Sources:
Durect Corp's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Durect Corp’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
